Last reviewed · How we verify

Current HAART regimen

Gilead Sciences · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Current HAART regimen is a Small molecule drug developed by Gilead Sciences. It is currently FDA-approved.

Current HAART (Highly Active Antiretroviral Therapy) regimens often involve the use of Raltegravir, a medication that targets the HIV virus, in combination with other treatments such as boosted protease inhibitors. This combination is used to manage conditions like HIV infections, AIDS, and pediatric HIV, as seen in clinical trials such as the SPIRAL study.

At a glance

Generic nameCurrent HAART regimen
SponsorGilead Sciences
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Current HAART regimen

What is Current HAART regimen?

Current HAART regimen is a Small molecule drug developed by Gilead Sciences.

Who makes Current HAART regimen?

Current HAART regimen is developed and marketed by Gilead Sciences (see full Gilead Sciences pipeline at /company/gilead).

What development phase is Current HAART regimen in?

Current HAART regimen is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing